Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO)
Belite Bio, Inc - American Depositary Shares (BLTE)
Company Research
Source: GlobeNewswire
SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in the upcoming Asia-Pacific Academy of Ophthalmology (APAO) 2026 Congress, taking place February 5-7, 2026 in Hong Kong. The presentations will include previously disclosed topline results from the Phase 3 DRAGON study of tinlarebant in adolescents with Stargardt disease type 1 (STGD1), as well as individual patient case reports from the study. Belite’s participation will include an oral presentation in a general scientific session, a sponsored lunch symposium, and an exhibition booth. Presentation DetailsSession: Inherited Retinal Disease and Miscellaneous Topics Title: Topline Results from the Phase 3 DRAGON Study of Tinlarebant for Adolescent Stargardt Diseas
Show less
Read more
Impact Snapshot
Event Time:
BLTE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLTE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLTE alerts
High impacting Belite Bio, Inc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BLTE
News
- Belite Bio (NASDAQ:BLTE) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $185.00 price target on the stock.MarketBeat
- Belite Bio On A Tear As It Approaches Key Regulatory Submissions [Seeking Alpha]Seeking Alpha
- Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1)GlobeNewswire
- Belite Bio (NASDAQ:BLTE) is now covered by analysts at Bank of America Corporation. They set a "buy" rating and a $195.00 price target on the stock.MarketBeat
- Belite Bio (NASDAQ:BLTE) was given a new $191.00 price target on by analysts at Morgan Stanley. They now have an "overweight" rating on the stock.MarketBeat
BLTE
Earnings
- 11/10/25 - Miss
BLTE
Sec Filings
- 1/30/26 - Form S-8
- 1/27/26 - Form 6-K
- 12/10/25 - Form SCHEDULE
- BLTE's page on the SEC website